Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Immanuel Luescher

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
Journal of Immunology (Baltimore, Md. : 1950)|December 26, 2008
An essential role for the stalk region of CD8 beta in the coreceptor function of CD8Lorna Rettig, Louise McNeill, Nitza Sarner, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 25, 2009
Vaccination with a recombinant protein encoding the tumor-specific antigen NY-ESO-1 elicits an A2/157-165-specific CTL repertoire structurally distinct and of reduced tumor reactivity than that elicited by spontaneous immune responses to NY-ESO-1-expressing TumorsGilles Bioley, Philippe Guillaume, Immanuel Luescher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 26, 2006
Active antiviral T-lymphocyte response can be redirected against tumor cells by antitumor antibody x MHC/viral peptide conjugatesValérie Cesson, Kathrin Stirnemann, Bruno Robert, et al.
Cancer Immunology, Immunotherapy : CII|November 15, 2011
Enhanced cytotoxicity and decreased CD8 dependence of human cancer-specific cytotoxic T lymphocytes after vaccination with low peptide doseTanja Lövgren, Petra Baumgaertner, Sébastien Wieckowski, et al.
Nature Immunology|May 7, 2013
T cells maintain an exhausted phenotype after antigen withdrawal and population reexpansionDaniel T Utzschneider, Amandine Legat, Silvia A Fuertes Marraco, et al.
Cancer Immunology, Immunotherapy : CII|February 7, 2008
Recognition of naturally processed and ovarian cancer reactive CD8+ T cell epitopes within a promiscuous HLA class II T-helper region of NY-ESO-1Junko Matsuzaki, Feng Qian, Immanuel Luescher, et al.
Immunity|October 16, 2004
T cell division and death are segregated by mutation of TCRbeta chain constant domainsEmma Teixeiro, Mark A Daniels, Barbara Hausmann, et al.
Vaccine|March 19, 2013
Establishment of animal models to analyze the kinetics and distribution of human tumor antigen-specific CD8⁺ T cellsDaisuke Muraoka, Hiroyoshi Nishikawa, Takuro Noguchi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2009
HLA class I - associated immunodominance affects CTL responsiveness to an ESO recombinant protein tumor antigen vaccineGilles Bioley, Philippe Guillaume, Immanuel Luescher, et al.
Frontiers in Immunology|August 29, 2022
CD8 T cell function and cross-reactivity explored by stepwise increased peptide-HLA versus TCR affinityPetra Baumgaertner, Julien Schmidt, Carla-Marisa Costa-Nunes, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
Journal of Immunology (Baltimore, Md. : 1950)|December 26, 2008
An essential role for the stalk region of CD8 beta in the coreceptor function of CD8Lorna Rettig, Louise McNeill, Nitza Sarner, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|February 25, 2009
Vaccination with a recombinant protein encoding the tumor-specific antigen NY-ESO-1 elicits an A2/157-165-specific CTL repertoire structurally distinct and of reduced tumor reactivity than that elicited by spontaneous immune responses to NY-ESO-1-expressing TumorsGilles Bioley, Philippe Guillaume, Immanuel Luescher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 26, 2006
Active antiviral T-lymphocyte response can be redirected against tumor cells by antitumor antibody x MHC/viral peptide conjugatesValérie Cesson, Kathrin Stirnemann, Bruno Robert, et al.
Cancer Immunology, Immunotherapy : CII|November 15, 2011
Enhanced cytotoxicity and decreased CD8 dependence of human cancer-specific cytotoxic T lymphocytes after vaccination with low peptide doseTanja Lövgren, Petra Baumgaertner, Sébastien Wieckowski, et al.
Nature Immunology|May 7, 2013
T cells maintain an exhausted phenotype after antigen withdrawal and population reexpansionDaniel T Utzschneider, Amandine Legat, Silvia A Fuertes Marraco, et al.
Cancer Immunology, Immunotherapy : CII|February 7, 2008
Recognition of naturally processed and ovarian cancer reactive CD8+ T cell epitopes within a promiscuous HLA class II T-helper region of NY-ESO-1Junko Matsuzaki, Feng Qian, Immanuel Luescher, et al.
Immunity|October 16, 2004
T cell division and death are segregated by mutation of TCRbeta chain constant domainsEmma Teixeiro, Mark A Daniels, Barbara Hausmann, et al.
Vaccine|March 19, 2013
Establishment of animal models to analyze the kinetics and distribution of human tumor antigen-specific CD8⁺ T cellsDaisuke Muraoka, Hiroyoshi Nishikawa, Takuro Noguchi, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 2, 2009
HLA class I - associated immunodominance affects CTL responsiveness to an ESO recombinant protein tumor antigen vaccineGilles Bioley, Philippe Guillaume, Immanuel Luescher, et al.
Frontiers in Immunology|August 29, 2022
CD8 T cell function and cross-reactivity explored by stepwise increased peptide-HLA versus TCR affinityPetra Baumgaertner, Julien Schmidt, Carla-Marisa Costa-Nunes, et al.
Pageof 3